These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

102 related articles for article (PubMed ID: 22275118)

  • 1. Inferential NMR/X-ray-based structure determination of a dibenzo[a,d]cycloheptenone inhibitor-p38α MAP kinase complex in solution.
    Honndorf VS; Coudevylle N; Laufer S; Becker S; Griesinger C; Habeck M
    Angew Chem Int Ed Engl; 2012 Mar; 51(10):2359-62. PubMed ID: 22275118
    [No Abstract]   [Full Text] [Related]  

  • 2. The third conformation of p38α MAP kinase observed in phosphorylated p38α and in solution.
    Akella R; Min X; Wu Q; Gardner KH; Goldsmith EJ
    Structure; 2010 Dec; 18(12):1571-8. PubMed ID: 21134636
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Targeting the hinge glycine flip and the activation loop: novel approach to potent p38α inhibitors.
    Martz KE; Dorn A; Baur B; Schattel V; Goettert MI; Mayer-Wrangowski SC; Rauh D; Laufer SA
    J Med Chem; 2012 Sep; 55(17):7862-74. PubMed ID: 22897496
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The discovery of novel protein kinase inhibitors by using fragment-based high-throughput x-ray crystallography.
    Gill A; Cleasby A; Jhoti H
    Chembiochem; 2005 Mar; 6(3):506-12. PubMed ID: 15696598
    [TBL] [Abstract][Full Text] [Related]  

  • 5. 5-amino-pyrazoles as potent and selective p38α inhibitors.
    Das J; Moquin RV; Dyckman AJ; Li T; Pitt S; Zhang R; Shen DR; McIntyre KW; Gillooly K; Doweyko AM; Newitt JA; Sack JS; Zhang H; Kiefer SE; Kish K; McKinnon M; Barrish JC; Dodd JH; Schieven GL; Leftheris K
    Bioorg Med Chem Lett; 2010 Dec; 20(23):6886-9. PubMed ID: 21035336
    [TBL] [Abstract][Full Text] [Related]  

  • 6. 3-Amino-pyrazolo[3,4-d]pyrimidines as p38α kinase inhibitors: design and development to a highly selective lead.
    Soth M; Abbot S; Abubakari A; Arora N; Arzeno H; Billedeau R; Dewdney N; Durkin K; Frauchiger S; Ghate M; Goldstein DM; Hill RJ; Kuglstatter A; Li F; Loe B; McCaleb K; McIntosh J; Papp E; Park J; Stahl M; Sung ML; Suttman R; Swinney DC; Weller P; Wong B; Zecic H; Gabriel T
    Bioorg Med Chem Lett; 2011 Jun; 21(11):3452-6. PubMed ID: 21515047
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Dynamics in the p38alpha MAP kinase-SB203580 complex observed by liquid-state NMR spectroscopy.
    Honndorf VS; Coudevylle N; Laufer S; Becker S; Griesinger C
    Angew Chem Int Ed Engl; 2008; 47(19):3548-51. PubMed ID: 18389508
    [No Abstract]   [Full Text] [Related]  

  • 8. Structure-based design, synthesis and biological evaluation of N-pyrazole, N'-thiazole urea inhibitors of MAP kinase p38α.
    Getlik M; Grütter C; Simard JR; Nguyen HD; Robubi A; Aust B; van Otterlo WA; Rauh D
    Eur J Med Chem; 2012 Feb; 48():1-15. PubMed ID: 22154891
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Benzothiazole based inhibitors of p38alpha MAP kinase.
    Liu C; Lin J; Pitt S; Zhang RF; Sack JS; Kiefer SE; Kish K; Doweyko AM; Zhang H; Marathe PH; Trzaskos J; Mckinnon M; Dodd JH; Barrish JC; Schieven GL; Leftheris K
    Bioorg Med Chem Lett; 2008 Mar; 18(6):1874-9. PubMed ID: 18296051
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Structural basis for the high-affinity binding of pyrrolotriazine inhibitors of p38 MAP kinase.
    Sack JS; Kish KF; Pokross M; Xie D; Duke GJ; Tredup JA; Kiefer SE; Newitt JA
    Acta Crystallogr D Biol Crystallogr; 2008 Jul; D64(Pt 7):705-10. PubMed ID: 18566506
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Discovery and characterization of MAPK-activated protein kinase-2 prevention of activation inhibitors.
    Cumming JG; Debreczeni JÉ; Edfeldt F; Evertsson E; Harrison M; Holdgate GA; James MJ; Lamont SG; Oldham K; Sullivan JE; Wells SL
    J Med Chem; 2015 Jan; 58(1):278-93. PubMed ID: 25255283
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Novel triazolopyridylbenzamides as potent and selective p38α inhibitors.
    Aiguadé J; Balagué C; Carranco I; Caturla F; Domínguez M; Eastwood P; Esteve C; González J; Lumeras W; Orellana A; Preciado S; Roca R; Vidal L; Vidal B
    Bioorg Med Chem Lett; 2012 May; 22(10):3431-6. PubMed ID: 22521646
    [TBL] [Abstract][Full Text] [Related]  

  • 13. MAP kinase p38 inhibitors: clinical results and an intimate look at their interactions with p38alpha protein.
    Lee MR; Dominguez C
    Curr Med Chem; 2005; 12(25):2979-94. PubMed ID: 16378500
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Two classes of p38alpha MAP kinase inhibitors having a common diphenylether core but exhibiting divergent binding modes.
    Michelotti EL; Moffett KK; Nguyen D; Kelly MJ; Shetty R; Chai X; Northrop K; Namboodiri V; Campbell B; Flynn GA; Fujimoto T; Hollinger FP; Bukhtiyarova M; Springman EB; Karpusas M
    Bioorg Med Chem Lett; 2005 Dec; 15(23):5274-9. PubMed ID: 16169718
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Optimized Target Residence Time: Type I1/2 Inhibitors for p38α MAP Kinase with Improved Binding Kinetics through Direct Interaction with the R-Spine.
    Wentsch HK; Walter NM; Bührmann M; Mayer-Wrangowski S; Rauh D; Zaman GJR; Willemsen-Seegers N; Buijsman RC; Henning M; Dauch D; Zender L; Laufer S
    Angew Chem Int Ed Engl; 2017 May; 56(19):5363-5367. PubMed ID: 28397331
    [TBL] [Abstract][Full Text] [Related]  

  • 16. 3,4-Diaryl-isoxazoles and -imidazoles as potent dual inhibitors of p38alpha mitogen activated protein kinase and casein kinase 1delta.
    Peifer C; Abadleh M; Bischof J; Hauser D; Schattel V; Hirner H; Knippschild U; Laufer S
    J Med Chem; 2009 Dec; 52(23):7618-30. PubMed ID: 19591487
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Discovery of 4-(5-(cyclopropylcarbamoyl)-2-methylphenylamino)-5-methyl-N-propylpyrrolo[1,2-f][1,2,4]triazine-6-carboxamide (BMS-582949), a clinical p38α MAP kinase inhibitor for the treatment of inflammatory diseases.
    Liu C; Lin J; Wrobleski ST; Lin S; Hynes J; Wu H; Dyckman AJ; Li T; Wityak J; Gillooly KM; Pitt S; Shen DR; Zhang RF; McIntyre KW; Salter-Cid L; Shuster DJ; Zhang H; Marathe PH; Doweyko AM; Sack JS; Kiefer SE; Kish KF; Newitt JA; McKinnon M; Dodd JH; Barrish JC; Schieven GL; Leftheris K
    J Med Chem; 2010 Sep; 53(18):6629-39. PubMed ID: 20804198
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Two conformers of 10,11-dihydro-5H-dibenzo[a,d]cycloheptene spiro-linked with homobenzoquinone epoxide.
    Asahara H; Koizumi T; Mochizuki E; Oshima T
    Acta Crystallogr C; 2006 Mar; 62(Pt 3):o136-8. PubMed ID: 16518049
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Design of potent and selective 2-aminobenzimidazole-based p38alpha MAP kinase inhibitors with excellent in vivo efficacy.
    de Dios A; Shih C; López de Uralde B; Sánchez C; del Prado M; Martín Cabrejas LM; Pleite S; Blanco-Urgoiti J; Lorite MJ; Nevill CR; Bonjouklian R; York J; Vieth M; Wang Y; Magnus N; Campbell RM; Anderson BD; McCann DJ; Giera DD; Lee PA; Schultz RM; Li LC; Johnson LM; Wolos JA
    J Med Chem; 2005 Apr; 48(7):2270-3. PubMed ID: 15801819
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Biological evaluation and structural determinants of p38α mitogen-activated-protein kinase and c-Jun-N-terminal kinase 3 inhibition by flavonoids.
    Goettert M; Schattel V; Koch P; Merfort I; Laufer S
    Chembiochem; 2010 Dec; 11(18):2579-88. PubMed ID: 21108268
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.